Objectives-To relate measurements and volume of the fetal adrenal gland in third trimester ultrasound in diabetic pregnancies (1) to birth weight; (2) to other sonographic markers of diabetic fetopathy (expected fetal weight, sectional area, and fractional volume in fetal limbs); and (3) to maternal biochemical markers of diabetes (HbA1c, leptin).
T he fetal adrenal gland is a highly specialized endocrine organ with an active role during the fetal development. The fetal gland shows a specific cortical compartment known as the fetal zone (FZ), which produces large amounts of steroids used for the placenta for estrogen biosynthesis. The human fetus has very large adrenal glands, easily recognizable by ultrasound as discoid anechoic structures with an echogenic inner zone (FZ). The FZ undergoes rapid involution after birth, so the total weight of the glands decreases by approximately 50%. 1 The steroid hormones produced by the adrenal gland regulate intrauterine homeostasis, the maturation of fetal organ systems, and the time of parturition. Previous works have shown the ultrasound measurements and volume of the fetal gland as valid predictors for preterm labor. [2] [3] [4] Other studies have demonstrated profound changes in the function and the morphology of the fetal adrenal gland in altered nutritional states-primarily undernutrition and/or intrauterine growth restriction in human and animal models. [5] [6] [7] [8] [9] Previous works have related the glycemic maternal control in gestational diabetes to diverse fetal changes, as increased fat tissue deposits in fetal limbs 10 or increased fetal liver size. 11 There are no studies yet examining the influence of maternal hyperglycemia on the ultrasonographic features of the fetal adrenal gland.
The objectives of the present study were to relate measurements and volume of the fetal adrenal gland in third-trimester ultrasound in diabetic pregnancies (1) to birth weight; (2) to other sonographic markers of diabetic fetopathy (expected fetal weight, sectional area, and fractional volume in fetal limbs) in third trimester; and (3) to maternal biochemical markers of diabetes (HbA1c, leptin) in third trimester.
Materials and Methods
This prospective study evaluates patients with gestational diabetes at the Obstetrics & Gynecology Department of Hospital Universitario Quiron Madrid (tertiary referral hospital for Maternal-Fetal Medicine). Subjects were randomly selected over a 1-year period commencing September 2014. Gestational diabetes screening was performed between 24 and 28 gestational weeks using a 50-g, 1-h glucose load test. Plasma glucose values greater than or equal to 140 mg/dL were considered screenpositive. Diagnostic testing was performed using a 100-g, 3-h oral glucose tolerance test. Women meeting National Diabetes Group criteria 12 were diagnosed with gestational diabetes and received nutritional counseling and instruction for glucose self-monitoring. The study was approved by the internal review board, and written informed consent was obtained from all patients. The exclusion criteria were pregestational diabetes mellitus, maternal hypertension, multiple pregnancy, congenital anomalies, and intrauterine growth restriction.
The following clinical maternal data were collected: age, gestational age at birth, nulliparity, neonatal weight, and birth weight percentile (according to neonatal growth charts that apply to our population by Spanish Pediatrics Society). 13 A third-trimester maternal peripheral venous blood sample was obtained between 32 1 0 and 34 1 0 weeks for each patient, in which HbA1c and leptin levels were determined. HbA1c was determined by a high-performance liquid chromatography method in a Bio-Rad Variant II analyzer (Bio-Rad Laboratories, Hercules, CA). Leptin was measured by enzyme immunoassay in a Triturus EIA analyzer (Grifols-Quest, Miami, FL).
All of the patients in this study underwent an ultrasound between 32 1 0 and 34 1 0 weeks using a Voluson E6 system (Voluson Expert, General Electric Medical Systems, Milwaukee, WI) with a 4-to 8-MHz curved transducer. Each patient underwent a single examination, and only one measurement from each participant was included for the statistical analysis. In each case, a routine standard sonographic study, including fetal anomaly screening and fetal biometry, was performed first. Adrenal gland and fetal limb volumes were obtained specifically for this study.
The fetal adrenal gland was identified as an anechoic structure with an echogenic center (FZ) located superior and medial to the ipsilateral kidney. The fetal adrenal gland closest to the probe was selected for analysis. The angle and depth settings were optimized to provide the best resolution. The fetal adrenal gland was scanned in a cross-sectional plane and a 3D block was obtained from only one adrenal gland for off-line analysis. The 3D volume acquisition box was adjusted to the region of interest to include the whole gland from a standard transversal plane. The volume block was checked to ensure that the gland contour was not distorted by interposition of structures before off-line storage. The blocks were analyzed by the same author (JGF) who was blinded to the pregnancy outcomes.
The dimensions of the fetal adrenal gland were measured within the blocks using multiplanar evaluation. The transverse plane was used as a reference to perform the multiplanar technique. Length was measured in transverse planes. Width was measured in coronal planes. Depth was measured in sagittal planes. All dimensions were registered three times in each patient and recorded. For each measurement, a total and a fetal zone value were recorded by marking the outer anechoic contour of the gland ("total") or the inner echogenic zone ("fetal zone"). The fetal zone to total ratio (FZ:T ratio) was calculated for each measurement ( Figure 1 ).
The volume of the gland was calculated with the VOCAL software package, 4D View (General Electric Medical Systems, Milwaukee, WI) as described previously. 4 Two independent volumes were obtained: total (delineating the outer anechoic limit of the gland) and fetal zone (delineating the echogenic inner core). These structures were outlined manually in six different planes. The fetal zone to total volume ratio was calculated and the corrected adrenal gland volume (c-AGV) was calculated by dividing the acquired total volume by the ultrasonographically estimated fetal weight ( Figure 2 ).
Fifteen cases were randomly selected to perform an intraobserver and interobserver reliability study. In each case, three full measurements were performed by the same blinded author (JGF) for the intraobserver study. Two full series of measurements were compared between two blinded authors for the intraobserver study.
Three-dimensional volumes from the fetal upper limb (arm) and lower limb (thigh) were obtained as described previously. 10 The fractional limb volumes were calculated using the 4D View software based on the central 50% of the diaphysis length. The crosssectional area was outlined in the middle sectional plane of the diaphysis. All of the measurements were obtained for total limb and central lean volume and area, and fat volume and area were obtained by subtracting lean from total value.
Quantitative results are reported as mean 6 SD, and qualitative results are expressed as number and percentages. Intraclass coefficients were calculated for each Figure 1 . Methodology for the measurement of the diameters of the fetal adrenal gland (1: fetal zone; 2: total). measurement using one-way random effects model. Univariate linear regression analysis was used to assess linear association between quantitative parameters. The measurements scoring P < .20 were further incorporated in a multivariate analysis model to predict birth weight and maternal biochemical markers. Statistical significance was reached at P < .05. Bonferroni's correction was used to adjust for multiple comparisons. Statistical analyses were carried out using the SPSS 18.0 software (IBM Analytics, Chicago, IL).
Results
A total of 39 diabetic pregnancies were included in this study. No patients were lost to follow-up, so full data from all patients were obtained. The mean maternal age was 34.9 6 4.18 years, and the rate of nulliparity was 64.1%. Mean gestational age at delivery was 38.8 6 1.18 weeks, with a cesarean-section rate of 20.5% (8/39) and an instrumental delivery rate of 25.6% (10/39). Seventeen of the 39 newborns were male (43.6%), and the mean birth weight was 3128.84 6 392.19 g, with a mean birth weight percentile of 48.6 6 30.01. The mean umbilical artery pH was 7.28 6 0.08, the mean Apgar score at minute 1 was 8.94 6 0.39 and the mean Apgar score at minute 5 was 9.87 6 0.33. Treatment with subcutaneous insulin was indicated in 21 patients (53.8%). Mean HbA1c value was 5.2% (60.57). Mean values and intraclass correlation coefficients for the sonographic measurements of the adrenal gland are displayed in Table 1 . Table 2 lists the univariate and multivariate regression analysis between fetal adrenal measurements by third trimester ultrasound and birth weight (absolute and percentile). Birth weight related significantly to total and FZ adrenal depth, and total adrenal volume in third trimester. Total adrenal length and c-AGV also showed a significant correlation to birth-weight percentile. In multivariate analysis, total gland volume displayed a significant association to birth weight (absolute), and c-AGV to birth weight (absolute and percentile).
The relations between fetal adrenal measurements and other fetal biometric markers in third trimester ultrasound are given in Tables 3 and 4 . The expected fetal weight (EFW) did not reach statistical significance when relating to any adrenal measurement ( Table 3) . The cross-sectional area measurements in both upper and lower limbs obtained some significant relations. Total adrenal volume gave the most consistent association, being significant in all of them (Table 3 ). The same pattern was observed between fetal adrenal gland measurements and fractional volumes in upper and lower limbs ( Table 4 ). The FZ:T ratio displayed an overall inverse relation to other measurements, reaching significance in most of the fractional volumes (Tables 3 and 4) . Both maternal leptin and HbA1c levels found a significant positive relation to fetal total adrenal volume and c-AGV. They also related significantly to other fetal adrenal measurements: maternal leptin related to total adrenal depth and FZ adrenal volume, and maternal HbA1c related to total adrenal length (Table 5 ). In multivariate analysis, total adrenal gland volume was the only independent significant variable related to maternal HbA1c level.
Discussion
To the best of our knowledge, this is the first work studying the effects of gestational diabetes on the sonographic features of the fetal adrenal gland. The gland volume related to birth weight, fat tissue volume in fetal limbs, and maternal biochemical markers of diabetes in third trimester. It may be concluded that an increased volume of the fetal adrenal gland is a sonographic feature of gestational diabetes. This enlarged size was particularly noticeable when measuring the total volume of the gland. It is implied that the growth could be higher in the definitive than in the FZ, as the FZ:T ratio showed a trend to negative correlation, which reached statistical significance in some values. The measurement of the fetal adrenal gland by ultrasound has been validated by previous studies regarding preterm labor. [2] [3] [4] 14 VOCAL has been the technique to demonstrate the highest diagnostic accuracy for determining the volume of the fetal gland, over bidimensional measurements. 15 In the present study, the total adrenal gland volume is the measurement used to obtain the most consistent association than other markers. Some other studies validate the c-AGV as a measurement of the adrenal gland not biased by the gestational age. 2 In our study, this value was not as useful, probably because of a narrow range of the gestational age when the ultrasound was performed.
The role of the fetal adrenal gland as a fetal metabolic regulator has been studied extensively in animal models reproducing intrauterine growth restriction models. [5] [6] [7] [8] [9] It has been proved that prenatal food restriction models alter the adrenal axis hormonal function and the gland size. There is also growing evidence linking these disorders with the intrauterine programming process and an increase in the susceptibility to adult metabolic diseases. Chronic hypoxic models also relate to adrenal function disturbance. 16 However, few models replicate the fetal hyperglycemia observed in the gestational diabetes. Some studies have suggested that perinatal hyperglycemia or overfeeding are related to adrenal function impairment. [17] [18] [19] Intrauterine infusion of IGF1 demonstrated adrenal growth in a sheep model. IGF1 is one of the anabolic fetal hormones that has been found to be increased in diabetic fetopathy. 20 All of these data imply that the fetal adrenal gland has a key role in the adaptation of the fetal metabolism to altered states of nutrition, and may have a central role in the physiopathology of the metabolic programming in theses fetuses. It may be hypothesized that the observed hypertrophy is not just a process secondary to a passive lipid deposit, but there are active cellular changes as a result of activation of steroidogenesis. This adrenal functional activation could also clarify the classical association between maternal diabetes and preterm labor. These affirmations should be endorsed by further evidence in future research. The tridimensional evaluation of the fetal adrenal gland offers some limitations as a result of its irregular shape. The intraobserver and interobserver study concludes that the length is the most reproducible measure in this work, probably because it is measured in the original plane of acquisition. Other bidimensional measurements from indirect planes obtained from postacquisition processing show a higher variation. The volume data are not apparently so affected by this possible bias. The contours of the gland are occasionally blurred when obtaining coronal or sagittal planes as a result of shadowing or lack of interfaces; thus, there might be some degree of guessing when delineating the gland. We consider that at least 75% of the gland contour in each image should be visualized when performing VOCAL rotational technique, and the final volume contours should be reviewed to check that they are properly adapted to the studied structure. The results from intraobserver and intraobserver studies are found to be acceptable when using this threshold.
The present study shows some limitations. The number of patients enrolled in this study was not large enough to provide statistical power to get more conclusive results in some analysis. This study is based on wellcontrolled pregnant patients with gestational diabetes, in which the fetal changes are expected to be mild. Thus, nonsignificant trends may be more conclusive when studying a higher risk population.
In conclusion, an enlargement of the fetal adrenal gland may be observed in gestational diabetes, not only related to birth weight, but also to distinctive features of diabetic pregnancies, such as fat tissue fetal deposits or maternal biochemical markers (HbA1c, leptin).
